Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark P Rubinstein

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Nature Immunology|March 28, 2026
ZFP148 is a transcriptional repressor of cytolytic effector CD8<sup>+</sup> T cell differentiationTong Xiao, Xingyu Chen, No-Joon Song, et al.
Cell Reports. Medicine|November 10, 2021
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinomaHannah M Knochelmann, Joshua D Horton, Sixue Liu, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
JCI Insight|February 7, 2023
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapyJoseph H Azar, John P Evans, Madison H Sikorski, et al.
Blood Advances|April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphomaNathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8<sup>+</sup> T-cell subsets in lymph nodes and tumorsVarghese K George, Hing C Wong, Martin Felices, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Nature Immunology|March 28, 2026
ZFP148 is a transcriptional repressor of cytolytic effector CD8<sup>+</sup> T cell differentiationTong Xiao, Xingyu Chen, No-Joon Song, et al.
Cell Reports. Medicine|November 10, 2021
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinomaHannah M Knochelmann, Joshua D Horton, Sixue Liu, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
JCI Insight|February 7, 2023
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapyJoseph H Azar, John P Evans, Madison H Sikorski, et al.
Blood Advances|April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphomaNathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8<sup>+</sup> T-cell subsets in lymph nodes and tumorsVarghese K George, Hing C Wong, Martin Felices, et al.
Pageof 8